Hoth Shares Rise After Alzheimer's Treatment Gets Patent

Dow Jones10-15

By Stephen Nakrosis

Shares of Hoth Therapeutics were trading higher in Tuesday's pre-opening market, following news the company was granted a U.S. patent for its Alzheimer's treatment, HT-ALZ.

The company said it is preparing for clinical trials of HT-ALZ, with formulation currently under way.

Before the bell, the stock had risen 29% to trade at $1.06. Shares last closed above $1 on Sept. 18.

The stock finished Monday's regular session at 82 cents, rising 9% on the day.

The company said its treatment takes a novel approach by targeting the Substance P/Neurokinin-1 Receptor pathway, which is known to play a critical role in neuroinflammation, increasingly recognized as a driving factor in the progression of Alzheimer's disease.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

October 15, 2024 06:58 ET (10:58 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2475881579?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-15 18:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2475881579","market":"sh","top_or_hot":-1,"title":"Hoth Shares Rise After Alzheimer's Treatment Gets Patent","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> were trading higher in Tuesday's pre-opening market, following news the company was granted a U.S. patent for its Alzheimer's treatment, HT-ALZ. \n</p>\n<p>\n  The company said it is preparing for clinical trials of HT-ALZ, with formulation currently under way. \n</p>\n<p>\n  Before the bell, the stock had risen 29% to trade at $1.06. Shares last closed above $1 on Sept. 18. \n</p>\n<p>\n  The stock finished Monday's regular session at 82 cents, rising 9% on the day. \n</p>\n<p>\n  The company said its treatment takes a novel approach by targeting the Substance P/Neurokinin-1 Receptor pathway, which is known to play a critical role in neuroinflammation, increasingly recognized as a driving factor in the progression of Alzheimer's disease. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 15, 2024 06:58 ET (10:58 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hoth Shares Rise After Alzheimer's Treatment Gets Patent</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHoth Shares Rise After Alzheimer's Treatment Gets Patent\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-15 18:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Stephen Nakrosis \n\n\n \n\n\n  Shares of Hoth Therapeutics were trading higher in Tuesday's pre-opening market, following news the company was granted a U.S. patent for its Alzheimer's treatment, HT-ALZ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1167","symbol_name":"电子制造服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2475881579","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475881579","pubTimestamp":1728989880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Hoth Therapeutics were trading higher in Tuesday's pre-opening market, following news the company was granted a U.S. patent for its Alzheimer's treatment, HT-ALZ.The company said it is preparing for clinical trials of HT-ALZ, with formulation currently under way.Before the bell, the stock had risen 29% to trade at $1.06. Shares last closed above $1 on Sept. 18.The stock finished Monday's regular session at 82 cents, rising 9% on the day.The company said its treatment takes a novel approach by targeting the Substance P/Neurokinin-1 Receptor pathway, which is known to play a critical role in neuroinflammation, increasingly recognized as a driving factor in the progression of Alzheimer's disease.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1167":"电子制造服务","01611":"新火科技控股","BK4007":"制药","HOTH":"Hoth Therapeutics"},"translate_title":"阿尔茨海默病治疗获得专利后霍斯股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01611":0.6,"HOTH":0.6},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Shares of Hoth Therapeutics were trading higher in Tuesday's pre-opening market, following news the company was granted a U.S. patent for its Alzheimer's treatment, HT-ALZ. \n\n\n  The company said it is preparing for clinical trials of HT-ALZ, with formulation currently under way. \n\n\n  Before the bell, the stock had risen 29% to trade at $1.06. Shares last closed above $1 on Sept. 18. \n\n\n  The stock finished Monday's regular session at 82 cents, rising 9% on the day. \n\n\n  The company said its treatment takes a novel approach by targeting the Substance P/Neurokinin-1 Receptor pathway, which is known to play a critical role in neuroinflammation, increasingly recognized as a driving factor in the progression of Alzheimer's disease. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 15, 2024 06:58 ET (10:58 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2475881579"}